Últimas noticias sobre CK Asset Holdings (OTC:CHKGF) Bolsa

CK Asset Holdings was the property business arm of the Cheung Kong Group before the spinoff in 2015. It was subsequently renamed CK Asset Holdings from CK Property in 2017. Li Ka-shing and his family remain the largest shareholders of CK Asset over the years, with about a 48% equity stake. The company mainly engages in property development, property investment, and hotel management in Hong Kong and mainland China, while diversifying into social housing, pub operations, and infrastructure management overseas in recent years.

CK Asset Holdings Ltd

Rosenblatt analyst Steve Frankel maintains Imax (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IMAX#NYSE">IMAX</a>) with a Buy and maintains $35 price target.

News

Price Target

Analyst Ratings

IMAX

Rosenblatt Maintains Buy on Imax, Maintains $35 Price Target

<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.lumen.com&amp;esheet=54276416&amp;newsitemid=20250615330222&amp;lan=en-US&amp;anchor=Lumen+Technologies%2C+Inc.&amp;index=1&amp;md5=16be0874577993a0c90075ad4b2b6765">Lumen Technologies, Inc.</a> ("Lumen", "us," "we" or "our") (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LUMN#NYSE">LUMN</a>) today announced that its wholly-owned subsidiary, Level 3 Financing, Inc. ("Level 3 Financing"), plans to offer $1.0 billion aggregate principal amount of First Lien Notes due 2033 (the "First Lien Notes").
Level 3 Financing intends to use the net proceeds from the offering, together with cash on hand, to redeem all $924.522 million aggregate principal amount of Level 3 Financing's first lien 10.500% Senior Secured Notes due 2030 (the "2030 Notes"), including payment of redemption premium, and to pay related fees and expenses.
The First Lien Notes will not be registered under the Securities Act of 1933 (the "Securities Act") or any state securities laws in the United States and may not be offered or sold in the United States absent registration or an exemption from the applicable registration requirements. Accordingly, the First Lien Notes are being offered and sold only to persons reasonably believed to be qualified institutional buyers in accordance with Rule 144A promulgated under the Securities Act and to non-U.S. persons outside the United States in accordance with Regulation S promulgated under the Securities Act. The First Lien Notes will not have registration rights.

Offerings

LUMN

Lumen Plans $1B Bond Offering to Pay Off High-Interest Debt and Cut Costs by 2030

Beyond Air, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XAIR#NASDAQ">XAIR</a>) will release its fourth-quarter financial results after the closing <a href="https://www.benzinga.com/quote/XAIR/earnings">bell on Tuesday, June 17</a>.
Analysts expect the Garden City, New York-based company to report quarterly revenue of $1.39 million, compared to $470,000 a year earlier, according to data from <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a>.
On April 21, Beyond Air announced its NeuroNOS subsidiary was granted an FDA Orphan Drug Designation.
Beyond Air shares fell 3% to close at $0.1779 on Friday.
Benzinga readers can access the latest analyst ratings on the <a href="https://www.benzinga.com/analyst-ratings/analyst-color/22/09/28888638/exclusive-study-finds-benzinga-analyst-ratings-data-yields-market-beating-strategie">Analyst Stock Ratings</a> page. Readers can sort by stock ticker, company name, analyst firm, rating change or other variables.
Let's have a look at how Benzinga's most-accurate <a href="https://www.benzinga.com/quote/xair/analyst-ratings">analysts </a><a href="https://www.benzinga.com/quote/GBX/analyst-ratings">have rated the company</a> in the recent period.
<ul class="wp-block-list">
<li>BTIG analyst Marie Thibault downgraded the stock from Buy to Neutral on June 25, 2024. This analyst has an accuracy rate of 63%.</li>
<li>Truist Securities analyst Gregory Fraser maintained a Buy rating and lowered the price target from $10 to $8 on April 30, 2024. This analyst has an accuracy rate of 63%.</li>
</ul>
Considering buying XAIR stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><a href="https://www.benzinga.com/quote/XAIR/analyst-ratings"><img loading="lazy" decoding="async" width="1024" height="611" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/16071841/image-233-1024x611.png" alt="" class="wp-image-950593" style="width:563px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/16071841/image-233-1024x611.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/16071841/image-233-300x179.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/16071841/image-233-768x458.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/16071841/image-233.png 1110w" sizes="(max-width: 1024px) 100vw, 1024px" /></a></figure>
Read This Next:
<ul class="wp-block-list">
<li> <a href="https://www.benzinga.com/trading-ideas/short-ideas/25/06/45924005/top-2-energy-stocks-that-may-fall-off-a-cliff-in-june">Top 2 Energy Stocks That May Fall Off A Cliff in June</a> </li>
</ul>
Photo via Shutterstock

Earnings

Markets

Trading Ideas

XAIR

Top Wall Street Forecasters Revamp Beyond Air Expectations Ahead Of Q4 Earnings

Rosenblatt analyst Kevin Cassidy maintains Canaan (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CAN#NASDAQ">CAN</a>) with a Buy and maintains $5 price target.

Rosenblatt Maintains Buy on Canaan, Maintains $5 Price Target

Adobe (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADBE#NASDAQ">ADBE</a>) on Monday announced at <a href="https://www.benzinga.com/pressreleases/25/06/b45943027/adobe-llm-optimizer-empowers-businesses-to-drive-brand-visibility-as-consumers-embrace-ai-powered-">the Cannes Lions International Festival of Creativity</a> the launch of Adobe LLM Optimizer, a new enterprise application designed to help businesses enhance brand relevance and visibility as consumers increasingly adopt generative AI-powered interfaces for brand engagement and discovery.
The core function of the LLM Optimizer is to equip businesses with the tools to monitor, analyze, and enhance their presence within Large Language Model (LLM) powered environments. 
This will allow companies to track traffic originating from AI-driven sources and compare their brand&#8217;s visibility against competitors. 
Also Read: <a href="https://www.benzinga.com/analyst-stock-ratings/analyst-color/25/06/45932918/adobe-stock-undervalued-analyst-says-as-it-breaks-from-cautious-tech-pack-lifts-guidance" target="_blank" rel="noreferrer noopener">Adobe Stock Undervalued, Says Analyst As It Breaks From Cautious Tech Pack, Lifts Guidance</a>
The system will then provide actionable recommendations to improve how a brand&#8217;s content is discovered and presented in AI-generated responses.
Highlighting the urgency and relevance of this new tool, Adobe shared insights from its own analytics, revealing a staggering 3,500% increase in traffic to U.S. retail sites from generative AI sources between July 2024 and May 2025. 
Adobe&nbsp;<a target="_blank" href="https://www.benzinga.com/pressreleases/25/06/b45943028/lumen-technologies-scales-b2b-personalization-with-generative-ai-innovations-in-adobe-genstudio" rel="noreferrer noopener">also announced that</a> Lumen Technologies (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LUMN#NYSE">LUMN</a>) is embracing&nbsp;Adobe GenStudio&nbsp;to activate generative AI across their organization, shortening the time it takes to deliver personalized business-to-business (B2B) marketing campaigns.
The collaboration has yielded impressive results, most notably reducing the time required to launch a B2B marketing campaign from 25 days down to just 9 days, the company said in a press release. 
This increased efficiency is driven by Adobe GenStudio for Performance Marketing, which uses generative AI to produce on-brand content for various digital channels, including social media and email.
Lumen is utilizing Adobe Firefly and Custom Models to quickly generate brand-compliant campaign imagery tailored to different audiences and industries. This has reduced the time to create ad variations by 65%.
The tools enable Lumen to scale the production of highly tailored content for B2B decision-makers across the 10 industries it serves, which is crucial for long and complex sales cycles.
By integrating solutions like Adobe Workfront for work management and Adobe Express for content creation, Lumen has simplified collaboration between its creative and marketing teams, ensuring a seamless approval process and brand consistency.
Price Action:&nbsp;ADBE stock is trading higher by 0.08% to $392.00 premarket at last check Monday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/analyst-stock-ratings/analyst-color/25/06/45928757/amd-serious-ai-contender-with-sights-on-over-500-billion-tam-billions-in-revenue-analyst" target="_blank" rel="noreferrer noopener">AMD &#8216;Serious AI Contender&#8217; With Sights On Over $500 Billion TAM, Billions In Revenue: Analyst</a></li>
</ul>
Photo by Charles-McClintock Wilson via Shutterstock

Tech

ADBE

Adobe To Help Brands Win The AI Search Game With New LLM Optimizer

Rosenblatt analyst Kevin Cassidy maintains Bitdeer Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BTDR#NASDAQ">BTDR</a>) with a Buy and maintains $20 price target.

BTDR

Rosenblatt Maintains Buy on Bitdeer Technologies, Maintains $20 Price Target

Updated Phase 2 data evaluating ZYNLONTA&#xAE; as a monotherapy demonstrate overall response rate (ORR) of 85% and complete response (CR) rate of 69%
CR maintained in 17 of 18 patients who achieved CR, with longest duration of CR of 27 months from start of treatment
ZYNLONTA was generally well tolerated and safety was consistent with known profile
LAUSANNE, Switzerland, June 16, 2025 /PRNewswire/ --&nbsp;ADC Therapeutics SA (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ADCT#NYSE">ADCT</a>), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced updated data&nbsp;from a Phase 2 multicenter investigator-initiated trial (IIT) of ZYNLONTA&#xAE; to treat relapsed/refractory marginal zone lymphoma (r/r MZL) will be presented during a poster session at the 18th International Conference on Malignant Lymphoma (ICML) in Lugano, Switzerland on Friday, June 20. These data will be made available online beginning on Wednesday, June 18,&nbsp;at 8:30 a.m. CEST. The single-arm, open-label, study is led by Izidore S. Lossos, MD, Chief, Division of Hematology Lymphoma Section, at Sylvester Comprehensive Cancer Center, part of the University of Miami Miller School of Medicine.

ADCT

ADC Therapeutics To Present Updated Data From Phase 2 Multicenter IIT Of ZYNLONTA To Treat r/r MZL, At International Conference on Malignant Lymphoma

Rosenblatt analyst Chris Brendler maintains Coinbase Global (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COIN#NASDAQ">COIN</a>) with a Buy and maintains $300 price target.

COIN

Rosenblatt Maintains Buy on Coinbase Global, Maintains $300 Price Target

RYVYL Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RVYL#NASDAQ">RVYL</a>) ("RYVYL" or the "Company"), a leading innovator of payment transaction solutions leveraging electronic payment technology, has submitted a registration statement on Form S-1 with the Securities and Exchange Commission. The number of shares to be offered and the price range for the proposed offering have not yet been determined. Additionally, management is executing strategic actions and enhancing its business plan:
<ul>
<li>RYVYL is
<ul>
<li>Focusing on growing its North America revenues, including pursuing a legacy vertical market, which at its peak, in the fourth quarter of 2023, delivered revenue of $12 million;</li>
<li>Expanding its blockchain applications and crypto capabilities; and</li>
<li>Rightsizing the company as detailed below.</li>
</ul>
</li>
<li>The company has entered into a letter of intent (LOI) to acquire an entity with technology and digital assets that are complementary.</li>
<li>RYVYL has closed the sale of RYVYL EU, its wholly owned European subsidiary, and the transaction is complete. The company has withdrawn its previous guidance for 2025.</li>
</ul>
Cost Savings Initiatives and Organizational Realignment
In addition, on May 31, 2025, RYVYL realigned its corporate and North America operations and implemented a reduction in force of 18 employees, representing approximately 40% of its North America workforce. Savings from this action along with other reductions are expected to result in savings of approximately $780,000 per quarter. Plans to reduce outside engineering contractors during the second quarter of 2025 are expected to result in savings of approximately $265,000 per quarter. The Company expects the full impact of these savings to begin in the third quarter of 2025.
Additional Terms
The offering is expected to commence after the SEC completes its review process, subject to market and other conditions. A registration statement relating to these securities has been filed with the SEC but has not yet become effective. These securities may not be sold, nor may offers to buy be accepted, prior to the time the registration statement becomes effective.
There are no assurances that the Company will close the acquisition or that the Enhanced Business Plan would result in a significant benefit to the Company. In addition, the Acquisition and Enhanced Business Plan would be dependent upon the Company raising a minimum of $100 million, which would require shareholder approval of (i) the Acquisition, (ii) a potential increase in the authorized amount of common stock of the Company, and (iii) a potential reverse split of the common stock of the Company.

IPOs

RVYL

RYVYL Files for Stock Offering, Plans Cost Cuts and Crypto Expansion to Refocus US Business

Fury Gold Mines Limited (NYSE:<a href="https://www.benzinga.com/stock/FURY#NYSE">FURY</a>) ("Fury" or the "Company") is pleased to announce that is has finalized a number of drill targets at the Sakami gold project located in the Eeyou Istchee Territory in the James Bay region of Northern Quebec (Figure 1). The first phase drilling campaign will commence in late June 2025 and will be comprised of approximately 3,000 – 5,000 metres (m), with three priorities;
<ol>
<li>Discovery along a 23-kilometre (km) long gold-bearing structural corridor at the Juliette target;</li>
<li>Confirm historical mineralized intercepts at the La Pointe and La Pointe Extension targets;</li>
<li>Stepout drilling along strike and down plunge of a high-grade corridor identified at La Pointe Extension.</li>
</ol>

FURY

Fury Gold Mines Finalizes Number Of Drill Targets At Sakami Gold Project Located In Eeyou Istchee Territory In James Bay Region Of Northern Quebec

AMWD

American Woodmark CFO Paul Joachimczyk Resigns, CEO Scott Culbreth Named Interim Financial Officer

<a href="https://www.globenewswire.com/Tracker?data=rv7o-H8l-jTHoqhdWSfawILWPvFTQwhluDyjODnmujzbKOlDii3m1SfQwRofUtfEQIuvCNgbSbw9HdyRZfS4gA==">USA Rare Earth</a>, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/USAR#NASDAQ">USAR</a>) (USAR or the Company) today announced it has signed a memorandum of understanding (MOU) with <a href="https://www.globenewswire.com/Tracker?data=BJyFqA3nAW4K9A56mCaK375RJQBr0MTWob_6mw-Dq2Q-GpnyRKzLGRYBdWxs0jE67QBXgZuFMgjslooskSXT5pQ1mbbNj7NjpL-sQzOLVAE=">Moog Electric Motion Solutions</a> (Moog) for delivery of the Company's neo magnets, of which USAR plans to begin production in early 2026. Moog Electric Motion Solutions provides precision motion and fluid control systems and will begin prototyping USAR's neo magnets for use in Moog's high-performance coolant distribution pumps used in data centers around the world.
The MOU is the latest in a series of agreements with potential customers announced by the Company following the March 31, 2025, commissioning of its Innovations Lab in Stillwater, Oklahoma. USAR's Innovations Lab mimics the production capabilities of the USAR's commercial manufacturing facility once commissioned in 2026. This capability now allows the Company to begin prototyping magnets and move through the qualification processes of potential customers, like Moog, as it seeks to scale up to its initial capacity next year.
"We continue our mission to bring the rare earth supply chain back to the broader technology market here in the U.S.," said Joshua Ballard, CEO of USA Rare Earth. "We are excited to support Moog in bringing their magnets back home to America, a leader in so many critical industries in need of neo magnetic applications. We look forward to building a lasting partnership for many years to come."
As part of the agreement, USA Rare Earth will design and test permanent Neodymium magnets for use in Moog's CoreMotion&#x2122; technology, which is driving energy efficiency in data centers deployed globally.

USAR

USA Rare Earth Partners With Moog to Bring Magnet Production Back to America for Global Data Centers

- CignaHealth becomes fifth major payer to authorize claim for PoNS Device at out-of-network adjusted negotiated list price of $19,161-
-This follows another recent authorization by Anthem Multiplan for PoNS Device at out-of-network negotiated price of $19,160-
NEWTOWN, Pa., June 16, 2025 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HSDT#NASDAQ">HSDT</a>) ("Helius" or the "Company"), a neurotech company focused on delivering a novel therapeutic neuromodulation approach for balance and gait deficits,&nbsp;today announced an additional authorized claim for payment for the PoNS Device from CignaHealth. CignaHealth becomes the fifth major payer to authorize claims for payment for the PoNS Device following the recent authorization by Anthem MultiPlan.
Depending on the individual's deductible and out-of-pocket costs, these claims may not result in an immediate PoNS Device sale.

HSDT

Helius Medical Technologies Announces Additional Authorized Claim For Payment For PoNS Device From CignaHealth

—Data across pediatric, adolescent, and adult populations demonstrate sustained reductions in HAE attacks and consistent safety profile—
—Patients report improved quality of life and daily functioning with ORLADEYO—

BCRX

BioCryst Reports Sustained Benefits Of Berotralstat in Children, Adolescents, And Adults With Hereditary Angioedema

Kirkland&#8217;s, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KIRK#NASDAQ">KIRK</a>) will release its first-quarter financial results before the opening <a href="https://www.benzinga.com/quote/KIRK/earnings">bell on Tuesday, June 17</a>.
Analysts expect the Brentwood, Tennessee-based company to report quarterly loss at 47 cents per share, versus a year-ago loss of 65 cents per share. Kirkland&#8217;s projects quarterly revenue of $85.56 million, compared to $91.75 million a year earlier, according to data from <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a>.
On May 1, Kirkland's reported disappointing fourth-quarter 2024 results and warned of substantial doubt over its ability to continue as a going concern.
Kirkland&#8217;s shares fell 4.8% to close at $1.19 on Friday.
Benzinga readers can access the latest analyst ratings on the <a href="https://www.benzinga.com/analyst-ratings/analyst-color/22/09/28888638/exclusive-study-finds-benzinga-analyst-ratings-data-yields-market-beating-strategie">Analyst Stock Ratings</a> page. Readers can sort by stock ticker, company name, analyst firm, rating change or other variables.
Let's have a look at how Benzinga's most-accurate <a href="https://www.benzinga.com/quote/KIRK/analyst-ratings">analysts have rated the company</a> in the recent period.
<ul class="wp-block-list">
<li>Benchmark analyst John Lawrence reiterated a Buy rating with a price target of $7 on Oct. 23, 2024. This analyst has an accuracy rate of 62%.</li>
<li>Craig-Hallum analyst Jeremy Hamblin maintained a Hold rating and lowered the price target from $2.5 to $2 on Sept. 6, 2024. This analyst has an accuracy rate of 68%.</li>
</ul>
Considering buying KIRK stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><a href="https://www.benzinga.com/quote/KIRK/analyst-ratings"><img loading="lazy" decoding="async" width="1024" height="589" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/16071130/image-232-1024x589.png" alt="" class="wp-image-950578" style="width:704px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/16071130/image-232-1024x589.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/16071130/image-232-300x172.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/16071130/image-232-768x441.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/16071130/image-232.png 1131w" sizes="(max-width: 1024px) 100vw, 1024px" /></a></figure>
Read This Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/trading-ideas/short-ideas/25/06/45924005/top-2-energy-stocks-that-may-fall-off-a-cliff-in-june">Top 2 Energy Stocks That May Fall Off A Cliff in June</a> </li>
</ul>
Photo via Shutterstock

KIRK

Kirkland's Gears Up For Q1 Print; Here Are The Recent Forecast Changes From Wall Street's Most Accurate Analysts

Tonix Pharmaceuticals Holding Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TNXP#NASDAQ">TNXP</a>) (Tonix or the Company) presented data in a poster presentation at the Annual European Congress of Rheumatology (EULAR) 2025, held June 11-14, 2025, in Barcelona, Spain. A copy of the Company's poster, titled "Advancing Fibromyalgia Treatment: Transmucosal Sublingual Cyclobenzaprine (TNX-102 SL) Targets Non-restorative Sleep and Provides Sustained Pain Reduction" is available under the <a href="https://www.globenewswire.com/Tracker?data=MBp6l1yE0UYuANFRaHcakT0YpPLwFdMkVv-sG5Z_BvnjCtvkoXNw7HPbhK1-zdW4JM1EJ2PYcf93TvQj_jWARwKm4AcWfMIGm6k0D9E8TBDogMAvA-Ed6lx7yGcevp8aCLRndB_H7jzMldmlI6vXVA==">Scientific Presentations</a> tab of the Tonix website at <a href="https://www.globenewswire.com/Tracker?data=mGj3zEWAkLkG6yt-vdOMKrNKcn4d98neV0wPM7Qwclwxuv_s5u9qn_RLBKTfU7dN12xCDJuWSLwAyNgezDAcmKLcaKhduNktLFfrz5YzCqE=">www.tonixpharma.com</a>. TNX-102 SL (cyclobenzaprine HCl sublingual tablets) is a non-opioid analgesic designed for daily bedtime dosing with an FDA Prescription Drug User Fee Act (PDUFA) goal date of August 15, 2025.

TNXP

Tonix Showcases New Fibromyalgia Drug That Targets Sleep and Pain Without Opioids

GTF maintenance agreement supports airline's long-term fleet plans
PARIS, June 16, 2025 /PRNewswire/ -- Pratt &amp; Whitney, an RTX (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RTX#NYSE">RTX</a>) business, and Cebu Pacific (CEB) have signed a long-term EngineWise&#x2122; comprehensive maintenance services agreement for the airline's GTF engine fleet. This agreement aligns Cebu Pacific's maintenance costs to the utilization of the airline's engines.
Currently, Cebu Pacific operates 56 Pratt &amp; Whitney powered aircraft. Prior to GTF engines, Pratt &amp; Whitney supplied JT8D engines for the airline's DC-9 aircraft fleet. Pratt &amp; Whitney and Cebu Pacific's relationship extends back to the 1990s.

RTX's Pratt & Whitney And Cebu Pacific Signs Long-Term EngineWise Comprehensive Maintenance Services Agreement For Airline's GTF Engine Fleet

Biotech

Health Care

General

OCGN

The FDA Clears Ocugen's Investigational New Drug Amendment To Initiate A Phase 2/3 Pivotal Confirmatory Trial Of OCU410ST, A Modifier Gene Therapy Candidate For All Stargardt Disease (ABCA-associated Retinopathies)

Pulmovant, a clinical-stage biotechnology company dedicated to developing innovative therapies to transform the treatment paradigm for adults suffering from pulmonary diseases and a <a href="https://www.globenewswire.com/Tracker?data=DpTIhaLdQLBte6PaVAS9H8dtbui0nzNvQvcgSeW3t9MPo7q9aXjeqGhMPmyY7008U_mXZZd2TzkLujYw8zh01w==">Roivant</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ROIV#NASDAQ">ROIV</a>) company, today announced the publication of Phase 1 pharmacokinetics (PK) in healthy male volunteers following the administration of mosliciguat, a potential first-in-class, inhaled soluble Guanylate Cyclase (sGC) activator with targeted delivery to the lungs and once-daily administration, designed to provide a treatment option for patients with pulmonary hypertension (PH). The peer-reviewed manuscript titled, "Pharmacokinetics and Lung Deposition After Administration of Inhaled Mosliciguat (BAY 1237592): Results from Randomized Phase I Studies in Healthy Men," was published in the scientific journal Clinical Pharmacokinetics. These data suggest inhaled mosliciguat has a longer half-life compared to oral and IV administration, supporting further evaluation of once-daily dosing and the potential to have limited systemic side effects when administered to patients.

ROIV

Pulmovant Unveils Phase 1 Results for Inhaled Drug Aiming to Treat Pulmonary Hypertension

TJ150 turbojet engines will power the multi-use Black Arrow missile&nbsp;
PARIS, June 16, 2025 /PRNewswire/ -- Pratt &amp; Whitney, an RTX (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RTX#NYSE">RTX</a>) business, has secured a contract from Dynetics, a Leidos company, to supply TJ150 engines to be integrated with their Small Cruise Missile, known as Black Arrow.
Although preliminary integration studies with Pratt &amp; Whitney commenced in 2023, work under this current contract began in April 2025 and will run through the first quarter of 2026. There is an option to provide follow-on quantities of engines. The TJ150 is in production today, and Pratt &amp; Whitney is continuing to improve upon the engine with a focus on affordability.

Comments

CK Asset Holdings

Noticias

Últimas noticias sobre CK Asset Holdings (OTC:CHKGF) Bolsa

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL